Ascletis Pharma Inc. (1672) reported the completion of enrollment for a U.S. Phase IIa study evaluating its once-monthly subcutaneous depot formulation of the small molecule GLP-1 receptor agonist ASC30 for obesity. According to official data, all 65 participants are obese or overweight with at least one weight-related comorbidity, and the 12-week randomized, double-blind, placebo-controlled, multi-center study is assessing safety, tolerability, and efficacy. Topline data are expected in the first quarter of 2026.

Previous research indicated a 46-day observed half-life of ASC30 in participants with obesity during a Phase Ib study, which supports once-monthly administration. The company revealed that ASC30’s ultra-long-acting subcutaneous depot treatment formulation demonstrated a terminal half-life of 36 days and a peak-to-trough ratio of approximately 1.5 to 1.

Ascletis Pharma Inc. stated that a conference call in Mandarin is scheduled on October 20, 2025, at 10:00 a.m. China Standard Time to further discuss this development. The investigational ASC30 GLP-1 receptor agonist, designed for both oral tablet and subcutaneous injection, remains protected by U.S. and global compound patents until 2044 without extensions.